SPPI Spectrum Pharmaceuticals Inc.

8.44
0  0%
Previous Close 8.44
Open
Price To Book 3.47
Market Cap 944,971,661
Shares 111,963,467
Volume 0
Short Ratio
Av. Daily Volume 799,235

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data from Cohort 1 due 4Q 2019. Cohort 2 data due mid-2020.
Poziotinib
Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2
Phase 2 initiation announced March 30, 2017 with preliminary data released October 18, 2017 - ORR 73%.
Poziotinib
Non-small cell lung cancer (NSCLC)
CRL received October 9, 2009. Approved April 29, 2011.
FUSILEV
Colorectal cancer
CRL received July 5, 2009.
ZEVALIN
Non-Hodgkin’s lymphoma
CRL October 23 2015. Approved March 15 2016.
EVOMELA (melphalan) for Injection
Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma
Failed to meet primary endpoint in Phase 3 trial - Apr 2012. PDUFA date December 11 2016. Advisory Committee Meeting September 14 2016 voted 14 - 0 against approval. CRL issued November 17, 2016. New Phase 3 trial initiation announced August 14, 2017.
QAPZOLA - Apaziquone
Bladder cancer
BLA withdrawn following request from FDA for further manufacturing information - March 15, 2019.
SPI-2012 (ROLONTIS)
Chemotherapy-Induced Neutropenia
Approved July 7, 2014.
Belinostat
Peripheral T-Cell Lymphoma cancer
Phase 2 data at ASH December 2018.
Leucovorin
Peripheral T-Cell Lymphoma cancer

Latest News

  1. Spectrum Pharmaceuticals Appoints Elizabeth Czerepak to its Board of Directors
  2. What Kind Of Investor Owns Most Of Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)?
  3. Ligand Inks Oncology Drug Discovery Deal With PhoreMost
  4. Why Is Spectrum Pharma (SPPI) Down 14.4% Since Last Earnings Report?
  5. Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting
  6. Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies 2019 Global Healthcare Conference on June 5th
  7. Spectrum Announces Poziotinib ZENITH20 Trial HER2 Cohort (Cohort 2) Has Reached Enrollment Target
  8. Edited Transcript of SPPI earnings conference call or presentation 9-May-19 8:30pm GMT
  9. Spectrum Pharmaceuticals to Present Corporate Update at the 20th Annual B. Riley FBR Investor Conference on May 23rd
  10. Spectrum Pharmaceuticals, Inc. (SPPI) Q1 2019 Earnings Call Transcript
  11. Spectrum Pharma (SPPI) Q1 Earnings Lag Estimates, Revenues Nil
  12. Spectrum Pharma: 1Q Earnings Snapshot
  13. Spectrum Pharmaceuticals Reports First Quarter 2019 Financial Results and Pipeline Update
  14. Spectrum Announces Asset Purchase and License for a Novel Immuno-Oncology Platform including Two Early Stage Assets
  15. Is Spectrum Pharmaceuticals, Inc. (SPPI) A Good Stock To Buy?
  16. Spectrum Pharmaceuticals Announces First Quarter 2019 Financial Results Conference Call
  17. Analysts Estimate Spectrum Pharmaceuticals (SPPI) to Report a Decline in Earnings: What to Look Out for
  18. The Spectrum Pharmaceuticals (NASDAQ:SPPI) Share Price Has Gained 66% And Shareholders Are Hoping For More
  19. Spectrum Pharmaceuticals to Present Corporate Update at the H.C. Wainwright Global Life Sciences Conference on April 9